Organon touts late-stage data for sugammadex

Organon says that its experimental anesthesia drug sugammadex was nine to 12 times better than standard therapy in reversing muscular block from anesthesia. The Phase III data compared sugammadex with neostigmine. "In the clinical trials until now sugammadex has generally demonstrated the ability to reverse shallow and profound depths of rocuronium-induced neuromuscular blockade within three minutes," Organon said. Organon--a subsidiary of Akzo Nobel--estimates the size of the market as more than half a billion dollars a year.

- check out the release for more information

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.